delisting not in the foreseeable future, imo. please proceed with the financial & legal advisors on plans to realize shareholder value through whatever means possible - and, big thanks (again) to McBride & Co. for putting this issue behind us!
good luck bashing Vivus when we once again have rights to market & SELL the LEADING, WORLD'S #1 E.D. DRUG WORLDWIDE!!!!!!
and, was the VVUS Board TRULY that NAIVE?!!?!?
to me, Endo was a waste of Stendra's valuable time "on the market"...then, to further delay success, they announce a re-launch that never happened...who's foolin' who?
money is currently there to spend advertising $$$ now....so, what is the marketing veep doing each day? "relationship-building"?
"BAGAS" up, GREEEEENNNN
furthermore, and strictly imo, this is a BOARD OF DIRECTORS issue, not simply an EXECUTIVE TEAM issue...where was the necessary diligence in overseeing advertising & marketing strategy for Stendra by AUXL/ENDP??? and, if successful, why not reported in conference calls? or, did I miss that part of the script?
if KTEAM2 is correct, it's all a setup for "management failure" despite opportunity of two phenomenal drugs, in order to gain control of the company from shareholders ...remember those two words if & when they are EVER used to portray current management as the reason for BK; THEN, and ONLY THEN, can the SVNT analogy be considered, imo, because executives can only be as effective as their Board of Directors allows.
I see Viagra & Cialis ALL THE FREAKING TIME!!!!!! why has Vivus not said a WORD about future marketing/advertising of Stendra when rights return???? why did Vivus not negotiate EARLIER RETURN OF MARKETING RIGHTS?!?!!?!?!
the question here is very obviously "does news of global opportunity actually penetrate the walls of Vivus HQ???"
I believe his bio says he "retired" from J&J in 2012...did Vivus actually hire him out of retirement to head up the company when Zook became ill???? is he truly vested (besides receiving inordinate compensation, imo, relative to his performance) in the success of Vivus? if so, why no emotion or optimism on conference calls? why the same old "poo-pooing" of the obesity market, when so many people are OBESE!??!?!
XXII Low Nicotine Technology Attempts to Curb $300B Smoking-Related Drag on US Economy
Medical care costs, lost productivity and second hand exposure pushed smoking’s economic drag to an overwhelming $300 billion . In 2009, The Tobacco Control Act granted FDA authority over the regulation of all tobacco products with aim of reducing nicotine in cigarettes. Accordingly, the established cigarette companies like Philip Morris (PM) and British American Tobacco (BTI) were required to moderate marketing efforts.
America’s smoking problem prompted regulatory change and presented an opportunity for 22nd Century’s (XXII) low nicotine cigarettes, which contain 95% less nicotine than conventional cigarettes according to the company. 22nd Century ran studies funded by the FDA’s Center for Tobacco Products to show that their low-nicotine cigarettes might reduce dependence on the addicting chemical and, consequently, the number of cigarettes smoked. This year, the company filed to receive the first FDA Modified Risk Tobacco Product (MRTP) designation, which would allow them to market their offering as the only ‘very low’ nicotine cigarette. Gaining this marketing edge could draw the attention of the big tobacco players and potentially encourage a licensing deal or acquisition worth hundreds of millions.
yes, why did he & the Board of Directors not announce significant changes to his management team via a press release, if indeed they did not?!!?!?!?!?!?
KTEAM2 visiting PFE, as well?!?!? does "FAILURE" ring a bell in KTEAM2 "cubical city"?!?!?!?
making the rounds this morning, KTEAM2?!?! how many times have you predicted "53 CENT" VVUS???? failure indeed...
I'm impressed...you are suggesting BUYING VIVUS??!!? LOLOOLOL!!!! change of thought over the weekend??? too much caffeine this morning?!?!?!
changes for VIVUS?!?!?!? was there ANY communication of the promotion of Deborah Larsen to VP Marketing, or Dr. Varghese to CMO!?!?!?! I DO NOT RECALL seeing these announcements, which are, imo, BOTH key to the future sales success of both Qsymia & Stendra/Spedra...so, if the moves were NOT announced, can someone tell me WHY?!!?!?
why, if we did NOT see communication, was this such a SECRET???? and, especially with the stock in the tank....comments? please do not refer to a 10K or 10Q (or even an 8K), which are NOT the only mediums for communication of COMPANY NEWS. Press releases are in order for the announcement of appointments of KEY EXECUTIVE OFFICERS!!!
if there was an announcement, please excuse my rant...
from a marketing standpoint, Vivus management continues to flail around like a cockroach on its backside...imo, the company's management & Board of Directors - who SUPPOSEDLY HAD ALL THE EXPERIENCE TO BRING THESE DRUGS TO MARKET SUCCESSFULLY - have failed shareholders to this point. hopefully, they will prove themselves deserving of compensation, bonuses, options, fees and whatever other rewards are being bestowed upon them by the comp committee.